Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Evaluation of Japanese and International Diagnostic Criteria for Idiopathic Castleman Disease

Makoto Ide, MD

Blood (2019) 134 (Supplement_1): 4873.

https://doi.org/10.1182/blood-2019-128212

Published: 2019

Journal Articles

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Mahmood B Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5461.

https://doi.org/10.1182/blood-2019-121654

Published: 2019

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

A Successful Experience with Brentuximab Vedotin in Relapsing/Refractory Cutaneous T-Cell Lymphoma: Two Case Reports

Liliya Gorenkova, PhD, Sergey K. Kravchenko, MD PhD, Alla M. Kovrigina, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2018) 132 (Supplement 1): 5371.

https://doi.org/10.1182/blood-2018-99-115829

Published: 2018

Journal Articles

When to Suspect Systemic Mastocytosis?

Sibel Kaplan, MD, Baris Kuskonmaz, MD, özge Ulusoy Soyer, Selin Aytaç, Fatma Gümrük

Blood (2018) 132 (Supplement 1): 5826.

https://doi.org/10.1182/blood-2018-99-119809

Published: 2018

Journal Articles

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Blood (2017) 129 (12): 1646–1657.

https://doi.org/10.1182/blood-2016-10-746933

Published: 2017

Journal Articles

Steroid Dependent Recalcitrant Well's Syndrome in a Patient with Chronic Lymphocytic Leukemia (CLL) Responding to Hydroxychloroquine (HCQS)

Prabhsimranjot Singh, MBBS, Makardhwaj S Shrivastava, MBBS, Audrik Perez, MD, Kenneth Grossman, MD, Daniel Benasher, MD, Alan Astrow, MD

Blood (2016) 128 (22): 5579.

https://doi.org/10.1182/blood.V128.22.5579.5579

Published: 2016

Journal Articles

Leukemic-Phase Diffuse Large B-Cell Lymphoma with t(14;18), CDKN2A and MLL Deletion Presenting with an Infiltrative Skin Rash

Iris Y Sheng, MD, Diana Olguta Treaba, MD, Kenneth D. Bishop, MD PhD

Blood (2016) 128 (22): 5419.

https://doi.org/10.1182/blood.V128.22.5419.5419

Published: 2016

Journal Articles

Concurrent Acute Kidney Injury with Vancomycin Use during the Engraftment Period in Patients Undergoing Autologous Stem Cell Transplant: A Single Institution Experience

Adolfo E Diaz-Duque, MD, Juan J. Toro, MD MSci, Francisca Cecilia Gushiken, MD

Blood (2016) 128 (22): 2208.

https://doi.org/10.1182/blood.V128.22.2208.2208

Published: 2016

Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Blood (2016) 128 (22): 4527.

https://doi.org/10.1182/blood.V128.22.4527.4527

Published: 2016

Journal Articles

Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management

David J Iberri, MD, Bernice Kwong, MD, Laurel Stevens, MD, Steven E Coutre, MD, Jinah Kim, MD PhD, Jean Sabile, BS, Ranjana H Advani, MD

Blood (2015) 126 (23): 4860.

https://doi.org/10.1182/blood.V126.23.4860.4860

Published: 2015

Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD

Blood (2015) 126 (23): 5116.

https://doi.org/10.1182/blood.V126.23.5116.5116

Published: 2015

Journal Articles

Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome

Ramona Cassin, MD, Gianluigi Reda, MD, Sonia Fabris, BSc, Nicola Orofino, MD, Bruno Fattizzo, MD, Umberto Gianelli, MD, Antonino Neri, Pr, MD, Agostino Cortelezzi, MD

Blood (2015) 126 (23): 5281.

https://doi.org/10.1182/blood.V126.23.5281.5281

Published: 2015

Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD

Blood (2014) 124 (21): 3450.

https://doi.org/10.1182/blood.V124.21.3450.3450

Published: 2014

Journal Articles

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Melhem M. Solh, MD, Tori Smith, Jason Balls, Megan Smith, Yasser Khaled, MD

Blood (2013) 122 (21): 5497.

https://doi.org/10.1182/blood.V122.21.5497.5497

Published: 2013

Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Blood (2013) 122 (21): 1496.

https://doi.org/10.1182/blood.V122.21.1496.1496

Published: 2013

Journal Articles

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Katherine Sutherland, Katherine Kong, Aaron C. Logan, MD, PhD, Malek Faham, MD, PhD, David B. Miklos, MD, PhD

Blood (2013) 122 (21): 1392.

https://doi.org/10.1182/blood.V122.21.1392.1392

Published: 2013

Journal Articles

Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report

Maxi Wass, MD, Timo Behlendorf, MD, Ulrike Gläser, MD, Jörn Rüssel, MD, Fredericke Güntsch, MD, Jordan Karin, MD, Hans-Joachim Schmoll, MD, PhD

Blood (2012) 120 (21): 4862.

https://doi.org/10.1182/blood.V120.21.4862.4862

Published: 2012

Journal Articles

ACE-536 Increases Hemoglobin in Healthy Postmenopausal Women: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study

Kenneth M Attie, MD, Ingrid E Boyd, Dawn M Wilson, Mark J Allison, MD, CPI, Matthew L Sherman, MD

Blood (2012) 120 (21): 3194.

https://doi.org/10.1182/blood.V120.21.3194.3194

Published: 2012

Journal Articles

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Jorge E. Cortes, MD, Jeffrey H. Lipton, MD, PhD, Carole B. Miller, MD, Sikander Ailawadhi, MD, Luke Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Felice P. Lin, PharmD, Solveig G. Ericson, MD, PhD, Michael J. Mauro, MD

Blood (2012) 120 (21): 3782.

https://doi.org/10.1182/blood.V120.21.3782.3782

Published: 2012

NARROW

Evaluation of Japanese and International Diagnostic Criteria for Idiopathic Castleman Disease

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

A Successful Experience with Brentuximab Vedotin in Relapsing/Refractory Cutaneous T-Cell Lymphoma: Two Case Reports

When to Suspect Systemic Mastocytosis?

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Steroid Dependent Recalcitrant Well's Syndrome in a Patient with Chronic Lymphocytic Leukemia (CLL) Responding to Hydroxychloroquine (HCQS)

Leukemic-Phase Diffuse Large B-Cell Lymphoma with t(14;18), CDKN2A and MLL Deletion Presenting with an Infiltrative Skin Rash

Concurrent Acute Kidney Injury with Vancomycin Use during the Engraftment Period in Patients Undergoing Autologous Stem Cell Transplant: A Single Institution Experience

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report

ACE-536 Increases Hemoglobin in Healthy Postmenopausal Women: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only